HORMA domain-containing protein 1 (HORMAD1) is a protein that promotes meiotic recombination and its expression is usually restricted to germ-line cells, although it has been shown to be actively expressed out of context in about 60% of triple-negative breast cancers (TNBCs). A team at The Institute of Cancer Research has found that this aberrant expression in tumor cells perturbs mitotic arrest and generates aneuploidy, leading to a weakening of the spindle assembly checkpoint and in kinetochore-microtubule error correction.

Researchers from Incyte Corp. reported the efficacy of INCB-161734, a KRAS G12D inhibitor, in combination with various strategies in models of pancreatic ductal adenocarcinomas (PDACs).

At the ESMO Targeted Anticancer Therapies Congress held this week in Paris, researchers at Mabqi SAS presented the preclinical characterization of MQI-201, an anti-TRPV6 therapeutic antibody in models of metastatic prostate cancer.

Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.

Researchers from Sungkyunkwan University and Txinno Bioscience Inc. recently presented their work where they aimed to design, synthesize and evaluate ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitors containing a benzotriazole core and a sulfonimidamide Zn binder.

Shanghai Henlius Biotech Inc. has presented preclinical data on HLX-403, its novel anti-CDH17 antibody-drug conjugate (ADC), highlighting its potential for gastrointestinal cancers. A first-in-human trial is expected to commence in the third quarter of this year.